Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck Sharp & Dohme LLC | 1,513 |
| 2 | Allergan Inc | 1,225 |
| 3 | Merck and Co Inc | 982 |
| 4 | F Hoffmann La Roche AG | 914 |
| 5 | Pfizer Inc | 758 |
| 6 | Eli Lilly and Co | 727 |
| 7 | Janssen Pharmaceutica NV | 618 |
| 8 | Dexcom Inc | 571 |
| 9 | Pfizer Corp SRL | 569 |
| 10 | Wyeth LLC | 514 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 52,295 |
| 2 | A61K | Medicinal preparations | 44,416 |
| 3 | C07D | Heterocyclic compounds | 26,243 |
| 4 | C07K | Peptides | 7,830 |
| 5 | G01N | Investigating / analysing materials | 6,549 |
| 6 | C07C | Acyclic and carbocyclic compounds | 6,083 |
| 7 | C12N | Microorganisms, enzymes | 5,214 |
| 8 | A61B | 4,240 | |
| 9 | A61N | 2,945 | |
| 10 | C12Q | Measuring/testing involving enzymes | 2,935 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Improvements in or relating to the preparation of l-arterenol and l-arterenol so prepared | 1951 | STWB Inc | 2 |
| NEW DRUG COMBINATIONS OF AN INHIBITOR OF THE RECOVERY OF NORADRENALINA (N.A.R.I.), PREFERENTLY REBOXETINA AND PINDOLOL. | 2005 | Pharmacia and Upjohn Co | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Neuroscience and Neuropharmacology Research | 50 |
| 2 | Neurotransmitter Receptor Influence on Behavior | 42 |
| 3 | Receptor Mechanisms and Signaling | 42 |
| 4 | Heart Rate Variability and Autonomic Control | 41 |
| 5 | Adipose Tissue and Metabolism | 39 |
| 6 | Neuropeptides and Animal Physiology | 35 |
| 7 | Neuroendocrine regulation and behavior | 27 |
| 8 | Nitric Oxide and Endothelin Effects | 24 |
| 9 | Diet and metabolism studies | 22 |
| 10 | Eicosanoids and Hypertension Pharmacology | 20 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Irwin J. Kopin | National Institute of Mental Health | 127 |
| 2 | Kjell Fuxé | Karolinska Institutet | 86 |
| 3 | Murray Esler | Baker Heart and Diabetes Institute | 73 |
| 4 | Klaus Starke | University of Freiburg | 71 |
| 5 | David S. Goldstein | National Institute of Neurological Disorders and Stroke | 62 |
| 6 | Gavin Lambert | Baker Heart and Diabetes Institute | 54 |
| 7 | Geoffrey Burnstock | University College London | 46 |
| 8 | Niels Juel Christensen | Herlev Hospital | 44 |
| 9 | Shigetoshi Chiba | Shinshu University | 42 |
| 10 | M. J. Rand | The University of Melbourne | 40 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Brown Adipose Tissue: Function and Physiological Significance | 2004 | 6394 | Adipokines, Inflammation, and Metabolic Diseases |
| AN INTEGRATIVE THEORY OF LOCUS COERULEUS-NOREPINEPHRINE FUNCTION: Adaptive Gain and Optimal Performance | 2005 | 4619 | Neurotransmitter Receptor Influence on Behavior |
| Stereotaxic Mapping of the Monoamine Pathways in the Rat Brain* | 1971 | 3819 | Neurotransmitter Receptor Influence on Behavior |
| A Systematic Method for Clinical Description and Classification of Personality Variants | 1987 | 3689 | Neurotransmitter Receptor Influence on Behavior |
| Stress and disorders of the stress system | 2009 | 3178 | Stress Responses and Cortisol |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Noradrop?
What are the main research topics associated with this compound?
Which pharmaceutical companies have filed the most patents related to Noradrop?
What are the most prolific authors publishing on this compound and their affiliations?
How much research and patenting activity surrounds Noradrop overall?